On June 7th, the U.S. Food and Drug Administration approved aducanumab, the first new Alzheimer’s treatment since 2003. Aducanumab is a monoclonal antibody that has been shown to reduce the buildup of a protein known as beta amyloid that some think might be a possible cause of Alzheimer’s disease. While the approval has been applauded by some, it is not without controversy. In this session, we ask our guests how innovation in the search for treatments of Alzheimer’s disease is evolving.
“Ideas to Innovation” is a podcast from Clarivate, a global leader in providing solutions to accelerate the lifecycle of innovation, helping customers solve some of the world’s most complex problems. Join Clarivate in conversations with experts and industry leaders to discuss innovation at its core, from science and research to intellectual property and beyond.